UNCY

Unicycive Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1766140Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(27.0M)

EPS (Basic, as reported)

$-1.67

Net Margin FY2025

—

ROE FY2025

-87.9%

Total Equity

$30.0M

Shares Out

28M

Business description

Unicycive Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 1 → 1 +0% CAGR

Fiscal yearFY2020⚑FY2021FY2022⚑FY2023⚑FY2024⚑FY2025

Revenue——11——

Research & development(1)(6)(12)(13)(20)(9)

Selling, general & administrative000———

General & administrative(1)(3)(7)(9)(12)(20)

Total operating expenses(2)(9)(19)(21)(32)(30)

Operating income(2)(9)(18)(21)(32)(30)

Interest expense0(1)0000

Interest & investment income———111

Other income (expense), net0(1)0(10)(5)3

Net income(2)(10)(18)(31)(37)(27)

EPS — basic($0.27)($0.86)($1.20)($1.28)($0.56)($1.67)

EPS — diluted—($0.86)($1.20)($1.28)($0.56)($1.67)

Shares outstanding — basic (M)81215256716

Shares outstanding — diluted (M)—1215256716

⚑ Weighted-average shares changed ×1.50 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.67 between FY2022 and FY2023 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×2.68 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ÷4.17 between FY2024 and FY2025 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.